Literature DB >> 7778919

No detection of Borrelia burgdorferi-specific DNA in erythema migrans lesions after minocycline treatment.

R R Muellegger1, N Zoechling, H P Soyer, S Hoedl, R Wienecke, M Volkenandt, H Kerl.   

Abstract

BACKGROUND AND
DESIGN: Early treatment of erythema migrans is important to prevent late complications. Minocycline possesses several attributes, making it potentially useful in the treatment of borrelial infections. In our study, minocycline was administered to 14 patients with erythema migrans. Punch biopsy specimens were obtained from the (affected) skin of all patients before and after therapy. The formalin-fixed, paraffin-embedded specimens were analyzed by polymerase chain reaction for the presence of Borrelia burgdorferi-specific DNA.
RESULTS: Polymerase chain reaction assay succeeded in amplifying B burgdorferi-specific DNA from the first biopsy specimen, obtained from the border of erythema migrans before initiating treatment, in eight (57%) of 14 patients. At the end of minocycline therapy, however, polymerase chain reaction analysis disclosed no B burgdorferi-specific DNA in any of the 14 patients. The good clinical response of our patients with erythema migrans substantiates our molecular findings.
CONCLUSIONS: The presented polymerase chain reaction data, together with the clinical outcome, indicate that minocycline may be useful for treatment of early Lyme borreliosis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7778919

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  9 in total

Review 1.  PCR in laboratory diagnosis of human Borrelia burgdorferi infections.

Authors:  B L Schmidt
Journal:  Clin Microbiol Rev       Date:  1997-01       Impact factor: 26.132

Review 2.  Diagnosis of lyme borreliosis.

Authors:  Maria E Aguero-Rosenfeld; Guiqing Wang; Ira Schwartz; Gary P Wormser
Journal:  Clin Microbiol Rev       Date:  2005-07       Impact factor: 26.132

3.  Diagnostic value of PCR for detection of Borrelia burgdorferi in skin biopsy and urine samples from patients with skin borreliosis.

Authors:  S Brettschneider; H Bruckbauer; N Klugbauer; H Hofmann
Journal:  J Clin Microbiol       Date:  1998-09       Impact factor: 5.948

4.  Success and failure in the treatment of acrodermatitis chronica atrophicans.

Authors:  E Aberer; F Breier; G Stanek; B Schmidt
Journal:  Infection       Date:  1996 Jan-Feb       Impact factor: 3.553

5.  Erythema migrans: three weeks treatment for prevention of late Lyme borreliosis.

Authors:  F Breier; G Kunz; H Klade; G Stanek; E Aberer
Journal:  Infection       Date:  1996 Jan-Feb       Impact factor: 3.553

6.  Polymerase chain reaction control of antibiotic treatment in dermatoborreliosis.

Authors:  R Muellegger; N Zoechling; E M Schluepen; H P Soyer; S Hoedl; M Volkenandt
Journal:  Infection       Date:  1996 Jan-Feb       Impact factor: 3.553

7.  Detection of Borrelia burgdorferi-specific DNA in urine specimens from patients with erythema migrans before and after antibiotic therapy.

Authors:  B Schmidt; R R Muellegger; C Stockenhuber; H P Soyer; S Hoedl; A Luger; H Kerl
Journal:  J Clin Microbiol       Date:  1996-06       Impact factor: 5.948

Review 8.  Minocycline as A Substitute for Doxycycline in Targeted Scenarios: A Systematic Review.

Authors:  Nicholas W Carris; Joe Pardo; Jose Montero; Kristy M Shaeer
Journal:  Open Forum Infect Dis       Date:  2015-11-25       Impact factor: 3.835

9.  Improved culture conditions for the growth and detection of Borrelia from human serum.

Authors:  Eva Sapi; Namrata Pabbati; Akshita Datar; Ellen M Davies; Amy Rattelle; Bruce A Kuo
Journal:  Int J Med Sci       Date:  2013-02-18       Impact factor: 3.738

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.